Balchem(BCPC) - 2025 Q1 - Quarterly Results

Financial Performance - Record net sales of $250.5 million, an increase of$10.9 million, or 4.5%, compared to the prior year quarter[5] - GAAP net earnings were $37.1 million, an increase of 27.8$66.3 million, an increase of 8.9% from the prior year quarter[5] - Net earnings for Q1 2025 were $37,053,000, a 28$28,986,000 in Q1 2024[21] - Adjusted net earnings for Q1 2025 were $40,017,000, compared to$33,584,000 in Q1 2024, representing a 19% increase[25] - EBITDA for Q1 2025 was $61,957,000, up from$55,273,000 in Q1 2024, indicating a 12% increase[27] Segment Performance - Human Nutrition and Health segment generated record sales of $158.5 million, an increase of$5.7 million, or 3.7% compared to the prior year quarter[8] - Animal Nutrition and Health segment generated quarterly sales of $57.3 million, an increase of$3.4 million, or 6.2% compared to the prior year quarter[8] - Specialty Products segment generated quarterly sales of $33.3 million, an increase of$1.7 million, or 5.3% compared to the prior year quarter[9] Cash Flow and Assets - Cash flows from operations were $36.5 million, with free cash flow of$31.0 million[12] - Free cash flow for Q1 2025 was $31,036,000, an increase from$26,815,000 in Q1 2024, marking an 15% growth[30] - Total assets as of March 31, 2025, were $1,617.6 million, an increase from$1,575.4 million at the end of 2024[19] Margins - Consolidated quarterly gross margin of $88.2 million increased by$6.7 million, or 8.2%, compared to the prior year comparable period[10] - Adjusted gross margin for Q1 2025 was $88,861,000, up from$82,218,000 in Q1 2024, reflecting a 8% increase[25] Tax and Dividends - The effective income tax rate for Q1 2025 was 22.7%, compared to 21.3% in Q1 2024[28] - Dividends paid in Q1 2025 totaled $28,263,000, compared to$25,555,000 in Q1 2024, reflecting an increase of 11%[21] Other Information - The company launched a new corporate website to enhance user experience and product insights[5] - Cash and cash equivalents at the end of Q1 2025 were $49,901,000, compared to$60,349,000 at the end of Q1 2024[21] - Capital expenditures for Q1 2025 were $5,559,000, down from$6,910,000 in Q1 2024, a decrease of 20%[21] - Proceeds from stock options exercised in Q1 2025 were $1,668,000, a significant decrease from$8,791,000 in Q1 2024[21]